(redirected from Tenofovir disoproxil)
Also found in: Medical, Wikipedia.


An antiviral drug, C9H14N5O4P, used in the form of a prodrug (tenofovir disoproxil fumarate) to treat chronic hepatitis B and, in combination with other drugs, to treat HIV infection or to reduce the risk of HIV infection.

[teno-, of unknown origin + fo- (alteration of pho(spho)-) + (anti)vir(al).]


n tenofovir m
Mentioned in ?
References in periodicals archive ?
Patients in four cohorts will be administered CRV431 in doses ranging from 75 mg to 375 mg in combination with 300 mg tenofovir disoproxil fumarate antiviral therapy, over a 28-day period.
Tenders are invited for acquisition of antiviral drugs: tenofovir disoproxil, emtricitabine / tenofovir disoproxil, efavirenz / emtricitabine / tenofovir disoproxil and entecavir-5 lots, for all hospitals in the madrid health service.
The victim compensation fund is being arranged for patients harmed after taking the company's TDF (tenofovir disoproxil fumarate) drugs as part of their treatment for HIV or AIDS or taken by uninfected individuals as part of the HIV prevention strategy called pre-exposure prophylaxis.
According to the company, Vemlidy is a novel, targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to Viread (tenofovir disoproxil fumarate, TDF) 300 mg, with better alanine aminotransferase normalisation and improved bone and renal safety at one-tenth of the dose.
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naive chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.
Yuen, Chief of Gastroenterology and Hepatology, University of Hong Kong, and Principal Investigator for the ACHIEVE trial, will show the full 24-week clinical and virological data from the 25mg, 50mg and 100mg cohorts of inarigivir monotherapy, including sequential dosing data following the switch from inarigivir to tenofovir disoproxil fumarate (Viread(r)).
Background: Tenofovir disoproxil (TDF) is a promising salvage therapy for patients with chronic hepatitis B (CHB) who failed regimens of other nucleoside analogues (NAs).
* Dolutegravir plus tenofovir disoproxil fumarate/emtricitabine (Tivicay plus Truvada).
HIV-infected patients with hepatitis B virus (HBV) coinfection should initiate a recommended ART regimen that contains tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF), lamivudine or emtricitabine, and a third component.
* Viread (tenofovir disoproxil fumarate; Gilead): Viread sees a net share gain from all but two surveyed brands.
One of the most commonly used drug among them for the first line therapy is Tenofovir Disoproxil Fumarate (TDF).
TAF is a novel targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to and at a dose less than one-tenth that of Gilead's Viread (tenofovir disoproxil fumarate, TDF).